[Severe course and contingent risk factors in optic neuropathy and myelopathy after tuberculostatics].
A male patient with tuberculous lymphadenopathy was treated with a four-fold therapy of ethambutol, isoniacide, rifampicin and pyracinamide. After 10 weeks the patient suffered from photophobia. Although ethambutol was discontinued vision decreased and visual field defects occurred as well as signs of myelopathy. Isoniacide was then discontinued and in the subsequent phase the vision was slowly restored over a period of 36 months. The combined toxicity of ethambutol and isoniacide seems to have been the main cause of the severe and protracted optic neuropathy.
Frisch
I B
IB
Universitäts-Augenklinik, Heidelberg. inez.frisch@hsk-wiesbaden.de
Kunze
A K
AK
Castro
A
A
Krastel
H
H
Meinck
H-M
HM
D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009901:Optic Nerve Diseases / Q000209:etiology* / Q000517:prevention & control; D020795:Photophobia / Q000209:etiology* / Q000517:prevention & control; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D012307:Risk Factors; D012308:Risk Management / Q000379:methods*; D013118:Spinal Cord Diseases / Q000209:etiology* / Q000517:prevention & control; D016896:Treatment Outcome; D014388:Tuberculosis, Lymph Node / Q000150:complications / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin